Drug Profile
Omodenbamab - XBiotech
Alternative Names: 514-G3; True human™ monoclonal antibody - XBiotechLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator XBiotech
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Staphylococcal infections
Most Recent Events
- 28 Sep 2021 Phase I/II trial is still ongoing for Staphylococcal infections in USA, Germany, Taiwan, South Korea (XBiotech pipeline, September 2021)
- 26 Oct 2018 XBiotech receives patent allowance for 514 G3 for the treatment of Staphylococcal infections and the True HumanTM antibody discovery platform in Australia, Canada, Israel, Mexico, Philippines, Russia and South Korea in the third quarter of 2018
- 10 Aug 2018 XBiotech plans a clinical trial (Prevention) for Staphylococcus infections in 2019